Exercise & Muscle
    Retatrutide

    Retatrutide and Strength Training: Beginner Program

    You do not need to be a gym veteran to protect your muscles during retatrutide weight loss. This beginner program gives you exactly what you need: simple exercises, clear instructions, and a progression plan that works even during caloric deficit.

    Published: April 3, 202614 min read

    Strength training is the most effective tool for preserving muscle during weight loss. On retatrutide -- which produces up to 24% body weight loss in Phase 2 trials (Jastreboff et al., NEJM 2023) -- it is not optional but essential. The good news: you do not need to lift heavy barbells or spend hours in a gym. A focused, beginner-friendly program using basic movements can provide the muscle-preserving stimulus your body needs.

    Safety First

    Consult your healthcare provider before starting any resistance training program. If you have joint issues, back problems, or other physical limitations, work with a certified personal trainer to modify exercises appropriately.

    Why Strength Training Is Non-Negotiable

    When your body is in the significant caloric deficit created by retatrutide, it looks for energy sources to make up the shortfall. Without a signal telling it to preserve muscle, it will break down both fat and muscle tissue. Strength training provides that signal -- every time you challenge a muscle against resistance, you communicate to your biology that the tissue is actively needed and should not be cannibalized for energy.

    Research consistently shows that caloric restriction without resistance training results in 25-35% of weight loss coming from lean mass. Adding resistance training reduces this to 10-20%. Over a 60-pound weight loss, that is the difference between losing 15-20 pounds of muscle versus 6-12 pounds. The practical impact on metabolic rate, physical function, and long-term weight maintenance is enormous.

    Phase 1: Foundation (Weeks 1-4)

    This phase teaches basic movement patterns using bodyweight and light resistance. Perform this routine 2 times per week with at least one rest day between sessions.

    Phase 1: Full Body Beginner Routine

    1. Bodyweight Squats: 2 sets of 10-15 reps

    Stand with feet shoulder-width apart. Lower your hips back and down as if sitting in a chair. Go as deep as comfortable, then stand back up. Hold a chair for balance if needed.

    2. Wall Push-Ups or Incline Push-Ups: 2 sets of 8-12 reps

    Place hands on a wall or elevated surface. Lower your chest toward the surface, then push back. The higher the surface, the easier the exercise. Progress to lower surfaces over time.

    3. Resistance Band Rows: 2 sets of 10-12 reps

    Anchor a resistance band at chest height. Pull the band toward your ribcage, squeezing your shoulder blades together. Control the return slowly.

    4. Step-Ups: 2 sets of 8-10 per leg

    Step onto a sturdy surface (6-12 inches high). Drive through the heel of the stepping leg. Step down under control. Alternate legs or complete all reps on one side before switching.

    5. Plank Hold: 2 sets of 15-30 seconds

    Hold a straight-body position on forearms and toes (or knees for beginners). Keep your core tight and body in a straight line. Build time gradually.

    Rest 60-90 seconds between sets. Total workout time: 20-30 minutes.

    Phase 2: Progression (Weeks 5-12)

    Once the foundation movements feel comfortable, progress to this intermediate routine. Increase to 3 sessions per week using an upper/lower split.

    Day A: Upper Body

    • Dumbbell bench press or push-ups: 3 sets of 8-12 reps
    • Dumbbell rows: 3 sets of 8-12 reps per arm
    • Overhead press (dumbbells): 2 sets of 10-12 reps
    • Bicep curls: 2 sets of 10-15 reps
    • Tricep dips (bench) or extensions: 2 sets of 10-15 reps

    Day B: Lower Body

    • Goblet squats (holding dumbbell): 3 sets of 8-12 reps
    • Romanian deadlifts (dumbbells): 3 sets of 8-10 reps
    • Walking lunges: 2 sets of 10 per leg
    • Glute bridges: 3 sets of 12-15 reps
    • Calf raises: 2 sets of 15-20 reps

    How to Progress Safely

    Progressive Overload Guidelines

    The 2-Rep Rule

    When you can complete 2 extra reps beyond your target on the last set (e.g., 14 reps when the target is 12), increase the weight by 2.5-5 pounds at the next session.

    Form Before Weight

    Never sacrifice form to lift heavier. Poor form increases injury risk and reduces the muscle stimulus. Controlled, full-range movements with lighter weight beat sloppy reps with heavy weight.

    Expect Slower Progress During Weight Loss

    In caloric deficit, strength gains are slower than when eating at maintenance or surplus. Maintaining current strength while losing significant body weight is itself a major achievement.

    Deload When Needed

    Every 4-6 weeks, reduce weight by 20-30% for one week. This allows joints and connective tissue to recover. Deload weeks are especially important during caloric deficit when recovery capacity is reduced.

    Common Beginner Mistakes on Retatrutide

    • Training too hard too soon: Excessive soreness and fatigue can discourage consistency. Start conservatively and build gradually.
    • Skipping workouts due to nausea: Light training on mild nausea days still provides muscle preservation benefit. Modify intensity rather than skipping entirely.
    • Neglecting protein around training: Consume 25-30 grams of protein within 2 hours of your workout. A protein shake is the easiest option when appetite is low.
    • Only doing cardio: Walking and cycling are excellent but do not provide the specific muscle-loading stimulus that resistance training delivers.
    • Comparing to others: Your body is adapting to both a new medication and a new exercise program simultaneously. Progress at your own pace.

    To explore currently available weight loss treatment options and discuss an exercise plan with a provider, visit our treatments page.

    Medical Disclaimer

    This article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug not yet approved by the FDA. Exercise programs should be individualized by a healthcare provider or certified fitness professional. Clinical data referenced is from Phase 2 trials (Jastreboff et al., NEJM 2023). Consult with a licensed healthcare provider before starting any exercise program.

    Build a Stronger, Leaner Body

    Expert-guided weight loss with comprehensive lifestyle support. Get started with a provider today.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 18, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook
    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Detailed comparison of retatrutide vs orforglipron: injectable triple agonist vs the first oral GLP-1 pill. Weight loss data, convenience, side effects, and which might be right for you.

    FDA approved oral Wegovy (semaglutide 50mg tablet) for weight loss in 2026. Review covers clinical trial results (~15% body weight loss), dosing, side effects, cost ($1,000–$1,500/mo), and affordable injectable alternatives.

    Detailed comparison of retatrutide vs tirzepatide: 24.2% vs 22.5% weight loss, mechanism differences, side effects, cost projections, and whether to wait or start now.

    Complete guide covering finding the best online weight loss doctors in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ingredients at u

    Start your GLP-1 journey — from $99/mo

    Get Started